Forest Laboratories, Inc. (FRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Forest Laboratories, Inc. (Forest Lab) is a pharmaceutical company focused on identifying, developing, manufacturing and marketing of pharmaceutical products including ethical and over the counter drugs in branded and generic forms. Forest Lab owns franchisees in the areas of cardiovascular, central nervous systems and others. The company is present in therapeutic areas including cardiovascular, central nervous system, endocrinology, pain management and respiratory. It also specializes in the development and launch of new products, including products developed in partnership with other companies. Forest Lab’s key prescription products include Lexapro, Namenda, Campral, Savella and Bystolic.
Forest Laboratories, Inc. Key Recent Developments
Jun 24, 2014: Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development
Apr 29, 2014: Forest Laboratories Reports Fiscal Year Fourth Quarter 2014
Mar 25, 2014: Glenmark Pharmaceuticals Ltd. through its Swiss Subsidiary receives USD 4 Mn. as research fee payment from Forest Laboratories
Jan 21, 2014: Forest Laboratories Reports Fiscal Year Third Quarter 2014
Jan 10, 2014: Forest Laboratories Names Karen L. Ling Senior Vice President, Chief Human Resources Officer
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Forest Laboratories, Inc. - Key Facts 6
Forest Laboratories, Inc. - Key Employees 7
Forest Laboratories, Inc. - Key Employee Biographies 8
Forest Laboratories, Inc. - Major Products and Services 9
Forest Laboratories, Inc. - Pharmaceutical Pipeline Products Data 10
Forest Laboratories, Inc., Pipeline Products by Therapy Area 10
Forest Laboratories, Inc., Pipeline Products by Development Phase 11
Forest Laboratories, Inc. - History 13
Forest Laboratories, Inc. - Company Statement 16
Forest Laboratories, Inc. - Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Section 2 – Company Analysis 20
Forest Laboratories, Inc. - Business Description 20
Forest Laboratories, Inc. - Corporate Strategy 22
Forest Laboratories, Inc. - SWOT Analysis 23
SWOT Analysis - Overview 23
Forest Laboratories, Inc. - Strengths 23
Strength - Comprehensive set of products 23
Strength - Strong R&D base 23
Strength - Increasing Profitability 23
Forest Laboratories, Inc. - Weaknesses 24
Weakness - Involvement in Litigations 24
Weakness - Concentration of revenues 24
Forest Laboratories, Inc. - Opportunities 24
Opportunity - Growing global pharmaceutical industry 24
Opportunity - Strategic Acquisitions 24
Opportunity - New drug approvals 24
Opportunity - Strategic Restructuring 25
Forest Laboratories, Inc. - Threats 25
Threat - Cost Containment Pressures 25
Threat - Uncertain R&D Outcomes 25
Threat - Competition and Technological Changes 25
Threat - Stringent regulation 26
Forest Laboratories, Inc. - Key Competitors 27
Section 3 – Company Financial Ratios 28
Financial Ratios - Capital Market Ratios 28
Financial Ratios - Annual Ratios 29
Performance Chart 30
Financial Performance 30
Financial Ratios - Interim Ratios 31
Financial Ratios - Ratio Charts 32
Section 4 – Company’s Lifesciences Financial Deals and Alliances 33
Forest Laboratories, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 33
Forest Laboratories, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014 34
Forest Laboratories, Inc., Recent Deals Summary 35
Section 5 – Company’s Recent Developments 36
Jun 24, 2014: Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development 36
Apr 29, 2014: Forest Laboratories Reports Fiscal Year Fourth Quarter 2014 36
Mar 25, 2014: Glenmark Pharmaceuticals Ltd. through its Swiss Subsidiary receives USD 4 Mn. as research fee payment from Forest Laboratories 39
Jan 21, 2014: Forest Laboratories Reports Fiscal Year Third Quarter 2014 39
Jan 10, 2014: Forest Laboratories Names Karen L. Ling Senior Vice President, Chief Human Resources Officer 41
Jan 02, 2014: Forest Laboratories Sets Date and Conference Call for Fiscal 2014 Third Quarter Earnings 42
Jan 02, 2014: Forest Laboratories Sets Date and Conference Call for Fiscal 2014 Third Quarter Earnings 42
Dec 09, 2013: Forest Laboratories Announces Appointments to its Executive Team 42
Nov 11, 2013: Forest Laboratories Names A. Robert D. Bailey Senior Vice President, Chief Legal Officer and General Counsel 43
Oct 25, 2013: Forest Laboratories names Alex Kelly Senior Vice President, Chief Communications Officer, Public Affairs and Investor Relations 43
Section 6 – Appendix 44
Methodology 44
Ratio Definitions 44
About GlobalData 48
Contact Us 48
Disclaimer 48
List Of Tables
List of Tables
Forest Laboratories, Inc., Key Facts 6
Forest Laboratories, Inc., Key Employees 7
Forest Laboratories, Inc., Key Employee Biographies 8
Forest Laboratories, Inc., Major Products and Services 9
Forest Laboratories, Inc., Number of Pipeline Products by Therapy Area 10
Forest Laboratories, Inc., Number of Pipeline Products by Development Stage 11
Forest Laboratories, Inc., Pipeline Products By Therapy Area and Development Phase 12
Forest Laboratories, Inc., History 13
Forest Laboratories, Inc., Other Locations 18
Forest Laboratories, Inc., Subsidiaries 18
Forest Laboratories, Inc., Key Competitors 27
Forest Laboratories, Inc., Ratios based on current share price 28
Forest Laboratories, Inc., Annual Ratios 29
Forest Laboratories, Inc., Interim Ratios 31
Forest Laboratories, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 33
Forest Laboratories, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014 34
Forest Laboratories, Inc., Recent Deals Summary 35
Currency Codes 44
Capital Market Ratios 44
Equity Ratios 45
Profitability Ratios 45
Cost Ratios 46
Liquidity Ratios 46
Leverage Ratios 47
Efficiency Ratios 47
List Of Figures
List of Figures
Forest Laboratories, Inc., Pipeline Products by Therapy Area 10
Forest Laboratories, Inc., Pipeline Products by Development Phase 11
Forest Laboratories, Inc., Performance Chart (2010 - 2014) 30
Forest Laboratories, Inc., Ratio Charts 32
Forest Laboratories, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 33
Forest Laboratories, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014 34
